Skip to main content
. 2018 Apr 10;9:43–50. doi: 10.2147/JBM.S129821

Table 2.

Efficacy parameters of bosutinib, nilotinib and dasatinib in first- and second-line treatment

Bosutinib Nilotinib Dasatinib
MMR rate after 24 months of first-line therapy 5919 7138 6439
CCyR rate of second line treatment after imatinib failure/intolerance 489 4140 4441

Abbreviations: CCyR, complete cytogenetic response; MMR, major molecular response.